Francis Medical Highlights Growing Focal Therapy Interest Around Vanquish System

A LinkedIn post from Francis Medical describes strong interest in focal therapy observed at the 41st Annual European Association of Urology Congress (EAU26). According to the post, high engagement in focal therapy sessions and plenary discussions suggested growing attention to precision-based treatment strategies in urology.

The post links this conference momentum to Francis Medical’s Vanquish Water Vapor Ablation System, which is positioned as a tool for targeted tissue ablation in focal therapy. For investors, the emphasis on rising clinical interest and the note that Vanquish is FDA cleared may indicate expanding adoption potential in urology practices, supporting the company’s growth prospects in minimally invasive prostate care.